Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest ACE inhibitor Stories

2012-11-28 13:15:59

A novel study from Karolinska Institutet in Sweden suggests that commonly used drugs to treat heart failure and high blood pressure may have a wider range of application than earlier known, and also can be used against so called HFPEF -- a type of heart failure that until now has been impossible to treat. The study, which is published in the scientific journal JAMA, shows that the mortality rate in a group of HFPEF patients who used these medications decreased. Heart failure affects 3 per...

2012-11-28 13:06:25

An analysis of two heart failure therapies finds differing outcomes regarding improvement in survival, according to two studies appearing in the November 28 issue of JAMA. In one study, Adrian F. Hernandez, M.D., M.H.S., of the Duke Clinical Research Institute, Durham, N.C., and colleagues examined the clinical effectiveness of aldosterone antagonist therapy and associations with long-term outcomes of older patients discharged from a hospitalization for heart failure. "Aldosterone...

2012-09-05 02:32:00

DEERFIELD, Ill., Sept. 5, 2012 /PRNewswire/ -- Results of a 10-week, phase 3 study published online in the American Journal of Medicine found the clinic systolic blood pressure (SBP) reductions of a fixed-dose combination of azilsartan medoxomil and chlorthalidone were significantly greater at six and ten weeks than those of azilsartan medoxomil co-administered with hydrochlorothiazide. Data also showed that more patients achieved their target blood pressure levels at the end of...

2012-06-27 17:45:21

Taxpayers could save millions of dollars if hospitals and provincial governments harmonized their prescription drug plans, new research suggests. Hospitals in Canada manage their formularies — the list of generic and brand-name drugs they dispense — independently. Yet many patients are discharged on medications they will have to purchase through publicly funded drug benefits programs. Dr. Chaim Bell, a physician and researcher at St. Michael's Hospital and scientist at the...

2012-06-19 02:24:47

DEERFIELD, Ill., June 19, 2012 /PRNewswire/ -- Results of a 12-week, head-to-head, phase 3 study published online in the American Heart Association journal Hypertension found systolic blood pressure (SBP) reductions of a fixed-dose combination of azilsartan medoxomil and chlorthalidone 40/25 mg were statistically superior to those of the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide 40/25 mg. This fixed-dose combination (azilsartan medoxomil and...

Link Between Blood Pressure Medication And PTSD Symptoms Discovered
2012-05-02 10:09:58

Image Credit: Photos.com --- Connie K. Ho for RedOrbit.com New findings from the Grady Trauma Project report that traumatized people who take a type of blood pressure medication often have less intense post-traumatic stress disorder (PTSD) symptoms. The results show that angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) could be used to help treat patients with PSTD. The study was conducted with over 5,000 low-income Atlanta residents who were...

2012-04-23 09:27:02

Results of study using animal model among the presentations at the meeting Experimental Biology 2012 Heart failure is the most common cause of death throughout the world, typically the result of chronic high blood pressure, also known as hypertension. As a result, research efforts have focused on an array of approaches aimed at preventing and treating high blood pressure. Recently, Japanese researchers examined the utility of an anti-hypertensive drug, moxonidine, which acts on the...

2012-02-22 14:50:22

A UCLA-led study has found that a combination of several key guideline-recommended therapies for heart failure treatment resulted in an improvment of up to 90 percent in the odds of survival over two years.   Heart failure, a chronic, progressive disease, affects millions of individuals and results in morbidity, the use of significant health care resources, and substantial costs.   While certain therapies are recommended for heart failure patients in the national guidelines of...

2012-02-06 06:00:00

DEERFIELD, Ill., and OSAKA, Japan, Feb. 6, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of hypertension to lower blood pressure in adults. It is the only fixed-dose therapy in the U.S. to combine an angiotensin II receptor blocker (ARB) with...

2011-12-20 14:49:00

DEERFIELD, Ill. and OSAKA, Japan, Dec. 20, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults. EDARBYCLOR is the only fixed-dose therapy in the U.S. to combine an angiotensin II...